TOCILIZUMAB

tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes

TOCILIZUMAB (12102Y)

tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes
12102Y
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 0 DPMQ: $801.70 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra Subcutaneous Injection